{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:17:52Z","timestamp":1790839072496,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02992","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:42:15Z","timestamp":1576852935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes"],"prefix":"10.3389","volume":"10","author":[{"given":"M\u00e9lissa","family":"Noack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Miossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"E938","DOI":"10.3390\/jcm8070938","article-title":"Current therapeutic options in the treatment of rheumatoid arthritis","volume":"8","author":"Kohler","year":"2019","journal-title":"J Clin Med"},{"key":"B4","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"B5","first-page":"S5","article-title":"Mechanisms of action of methotrexate","volume":"71","author":"Chan","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1073\/pnas.88.6.2441","article-title":"Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells","volume":"88","author":"Cronstein","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-016-1046-6","article-title":"Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion","volume":"18","author":"Noack","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/cei.12830","article-title":"Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells","volume":"186","author":"Noack","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fimmu.2016.00509","article-title":"Evaluation of anti-inflammatory effects of steroids and arthritis-related biotherapies in an in vitro coculture model with immune cells and synoviocytes","volume":"7","author":"Noack","year":"2016","journal-title":"Front Immunol"},{"key":"B11","volume-title":"IL-17\/Th17 During Chronic Inflammation: Targeting of Cellular Interactions [Sciences, Immunology]","author":"Noack","year":"2016"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/art.34391","article-title":"Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis","volume":"64","author":"Eljaafari","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","article-title":"Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers","volume":"12","author":"Brown","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1210\/er.2014-1010","article-title":"Comprehensive overview of the structure and regulation of the glucocorticoid receptor","volume":"35","author":"Vandevyver","year":"2014","journal-title":"Endocr Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/annrheumdis-2016-209212","article-title":"Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial","volume":"76","author":"Verschueren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13075-017-1378-x","article-title":"Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy","volume":"19","author":"Teitsma","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"E657","DOI":"10.3390\/cells8070657","article-title":"Post-translational modifications of proteins: novel insights in the autoimmune response in rheumatoid arthritis","volume":"8","author":"Carubbi","year":"2019","journal-title":"Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1365-2249.1999.00753.x","article-title":"Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression","volume":"115","author":"Neurath","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1186\/ar4444","article-title":"Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937","volume":"16","author":"Olsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1136\/annrheumdis-2015-208426","article-title":"Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)","volume":"75","author":"Kaneko","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/ard.2007.076166","article-title":"The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy","volume":"67","author":"van der Heijde","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/ar3537","article-title":"Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis","volume":"13","author":"Guyot","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T14:42:18Z","timestamp":1576852938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2019.02992"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02992","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"article-number":"2992"}}